TrialOphthalmology2021

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor.

M Teresa Magone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.